THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN ACUTE PHASE OF SCHIZOPHRENIA IN TURKEY
Author(s)
Bilge Kanbur, MD, Health Economics Manager1, Oguz Karamustafalioglu, MD, Assoc. Prof. Dr2, Nesrin Dilbaz, MD, Assoc. Prof. Dr3, Solmaz Turkcan, MD, Assoc. Prof. Dr4, Fatih Sarioz, MD, Health Economics Manager1, Fahreddin Tatar, PhD, Health Policy Director11Janssen-Cilag, Istanbul, Turkey; 2 Sisli Etfal Training and Research Hospital, Istanbul, Turkey; 3 Ankara Numune Training and Research Hospital, Ankara, Turkey; 4 Bakirkoy Mental Diseases Training and Research Hospital, Istanbul, Turkey
OBJECTIVES:Schizophrenia is a chronic illness with great economic burden. Paliperidone ER is a new atypical antipsychotic drug in Turkey. The aim of the study is to estimate the cost-effectiveness of paliperidone ER compared to other oral atypicals (risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole) in acute phase of schizophrenia.METHODS:Model: An existing decision analytic model is adapted (based on literature and expert panels). The time horizon is six weeks. The study is performed from the health care payer perspective.Patient group: Patients diagnosed with schizophrenia that have suffered an acute exacerbation.Data sources: The clinical data are acquired from the literature. Resource use data are derived via expert panel. Prices of medications, institutional discount rates and other costs related to the treatment are obtained from Ministry of Health Drug Price List, Price List of Social Security Institution Health Implementation Guideline Appendix 2/D, 8 and 9, respectively.Clinical and economic outcomes: The clinical outcome measure is the number of patients responding. The response rate describes the proportion of patients who benefited from the therapy. This is defined as those achieving decrease of 30% or above to baseline in total PANSS score. Only direct medical costs, i.e. costs of antipsychotics, treatment of side effects, physician visits, hospitalization and laboratory examinations are considered. The results are presented as (ICER) additional cost per additional patient responding.RESULTS:Results are as follows: Total costs: €488, €444, €459, €629, €732, €712; response rates: 0.42, 0.36, 0.41, 0.33, 0.30, 0.32 for paliperidone, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole respectively. ICER is €760/responder for paliperidone. One-way sensitivity analyses prove that results of the study are strong.CONCLUSIONS:In the acute phase of schizophrenia, paliperidone is the dominant therapy in comparison to quetiapine, ziprasidone and aripiprazole. Compared to risperidone and olanzapine, it is the cost-effective therapy option.
Conference/Value in Health Info
2008-11, ISPOR Europe 2008, Athens, Greece
Value in Health, Vol. 11, No. 6 (November 2008)
Code
PMH16
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Mental Health
Explore Related HEOR by Topic